Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Untch

Showing results (261-270 of 377) with videos related to

Pageof 38
Sort By:
NPJ Breast Cancer|July 30, 2024
GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancerVolker Möbus, Hans-Joachim Lück, Ekkehart Ladda, et al.
Breast Care (Basel, Switzerland)|April 2, 2020
International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus - Assessment by a German Group of ExpertsChristoph Thomssen, Diana Lüftner, Michael Untch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2013
Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative studyFrédéric Amant, Gunter von Minckwitz, Sileny N Han, et al.
International Journal of Molecular Sciences|February 23, 2020
Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant TherapySerena Di Cosimo, Valentina Appierto, Sara Pizzamiglio, et al.
Geburtshilfe Und Frauenheilkunde|March 13, 2023
Update Breast Cancer 2022 Part 6 - Advanced-Stage Breast CancerDiana Lüftner, Michael P Lux, Tanja N Fehm, et al.
JAMA Oncology|March 13, 2020
Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical TrialEsther Pohl-Rescigno, Jan Hauke, Sibylle Loibl, et al.
The Lancet. Oncology|February 13, 2016
Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trialMichael Untch, Christian Jackisch, Andreas Schneeweiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2014
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancerSibylle Loibl, Gunter von Minckwitz, Andreas Schneeweiss, et al.
Geburtshilfe Und Frauenheilkunde|March 13, 2023
Update Breast Cancer 2022 Part 5 - Early Stage Breast CancerTanja N Fehm, Manfred Welslau, Volkmar Müller, et al.
The Lancet. Oncology|May 6, 2014
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trialGunter von Minckwitz, Andreas Schneeweiss, Sibylle Loibl, et al.
Pageof 38

Showing results (261-270 of 377) with videos related to

Sort By:
Pageof 38
NPJ Breast Cancer|July 30, 2024
GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancerVolker Möbus, Hans-Joachim Lück, Ekkehart Ladda, et al.
Breast Care (Basel, Switzerland)|April 2, 2020
International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus - Assessment by a German Group of ExpertsChristoph Thomssen, Diana Lüftner, Michael Untch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2013
Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative studyFrédéric Amant, Gunter von Minckwitz, Sileny N Han, et al.
International Journal of Molecular Sciences|February 23, 2020
Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant TherapySerena Di Cosimo, Valentina Appierto, Sara Pizzamiglio, et al.
Geburtshilfe Und Frauenheilkunde|March 13, 2023
Update Breast Cancer 2022 Part 6 - Advanced-Stage Breast CancerDiana Lüftner, Michael P Lux, Tanja N Fehm, et al.
JAMA Oncology|March 13, 2020
Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical TrialEsther Pohl-Rescigno, Jan Hauke, Sibylle Loibl, et al.
The Lancet. Oncology|February 13, 2016
Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trialMichael Untch, Christian Jackisch, Andreas Schneeweiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2014
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancerSibylle Loibl, Gunter von Minckwitz, Andreas Schneeweiss, et al.
Geburtshilfe Und Frauenheilkunde|March 13, 2023
Update Breast Cancer 2022 Part 5 - Early Stage Breast CancerTanja N Fehm, Manfred Welslau, Volkmar Müller, et al.
The Lancet. Oncology|May 6, 2014
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trialGunter von Minckwitz, Andreas Schneeweiss, Sibylle Loibl, et al.
Pageof 38